Nektar Therapeutics – LSE:0UNL.L
Nektar Therapeutics stock price today
Nektar Therapeutics stock price monthly change
Nektar Therapeutics stock price quarterly change
Nektar Therapeutics stock price yearly change
Nektar Therapeutics key metrics
Market Cap | 162.96M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.92 |
Revenue | 90.16M |
EBITDA | -118.94M |
Income | -175.84M |
Revenue Q/Q | 0.20% |
Revenue Y/Y | 1.50% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -131.92% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNektar Therapeutics stock price history
Nektar Therapeutics stock forecast
Nektar Therapeutics financial statements
| Jun 2023 | 20.49M | -51.12M | -249.39% |
|---|---|---|---|
| Sep 2023 | 24.14M | -45.83M | -189.85% |
| Dec 2023 | 23.88M | -42.07M | -176.17% |
| Mar 2024 | 21.63M | -36.80M | -170.07% |
| Sep 2025 | 19M | -48.31M | -254.28% |
|---|---|---|---|
| Oct 2025 | 22.8M | -30.18M | -132.39% |
| Dec 2025 | 22.65M | -32.13M | -141.87% |
| Mar 2026 | 19M | -50.01M | -263.23% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 494279000 | 297.32M | 60.15% |
|---|---|---|---|
| Sep 2023 | 442244000 | 282.87M | 63.96% |
| Dec 2023 | 398033000 | 267.04M | 67.09% |
| Mar 2024 | 396012000 | 269.30M | 68% |
| Jun 2023 | -51.52M | 25.17M | 18K |
|---|---|---|---|
| Sep 2023 | -42.12M | 56.41M | -64.92M |
| Dec 2023 | -47.04M | 17.38M | 12K |
| Mar 2024 | -47.88M | 19.25M | 42.00M |
Nektar Therapeutics alternative data
| Aug 2023 | 216 |
|---|---|
| Sep 2023 | 216 |
| Oct 2023 | 216 |
| Nov 2023 | 216 |
| Dec 2023 | 216 |
| Jan 2024 | 216 |
| Feb 2024 | 216 |
| Mar 2024 | 137 |
| Apr 2024 | 137 |
| May 2024 | 137 |
| Jun 2024 | 137 |
| Jul 2024 | 137 |
Nektar Therapeutics other data
| Insider | Compensation |
|---|---|
| Mr. Howard W. Robin (1953) Chief Executive Officer, Pres & Director | $1,190,000 |
Mr. Gilbert M. Labrucherie (1972) Senior Vice President, Chief Financial Officer & Chief Operating Officer | $695,820 |
| Dr. Jonathan Zalevsky (1975) Chief R&D Officer | $590,120 |
| Ms. Jillian B. Thomsen (1966) Senior Vice President of Fin. & Chief Accounting Officer | $470,790 |
Mr. John P. Northcott (1978) Senior Vice President & Chief Commercial Officer | $269,560 |
Mr. Mark A. Wilson Senior Vice President, Gen. Counsel & Sec. | |
| Dr. Mary Tagliaferri Senior Vice President & Executive Clinical Fellow | |
| Dr. Brian L. Kotzin Senior Vice President of Clinical Devel. & Head of Immunology Program | |
Dr. Kevin Brodbeck Senior Vice President of Manufacturing | |
Ms. Jennifer Ruddock Senior Vice President of Strategy & Corporation Affairs |
-
What's the price of Nektar Therapeutics stock today?
One share of Nektar Therapeutics stock can currently be purchased for approximately $13.56.
-
When is Nektar Therapeutics's next earnings date?
Unfortunately, Nektar Therapeutics's (0UNL.L) next earnings date is currently unknown.
-
Does Nektar Therapeutics pay dividends?
No, Nektar Therapeutics does not pay dividends.
-
How much money does Nektar Therapeutics make?
Nektar Therapeutics has a market capitalization of 162.96M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 2.1% to 90.12M US dollars.
-
What is Nektar Therapeutics's stock symbol?
Nektar Therapeutics is traded on the LSE under the ticker symbol "0UNL.L".
-
What is Nektar Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Nektar Therapeutics?
Shares of Nektar Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Nektar Therapeutics's key executives?
Nektar Therapeutics's management team includes the following people:
- Mr. Howard W. Robin Chief Executive Officer, Pres & Director(age: 72, pay: $1,190,000)
- Mr. Gilbert M. Labrucherie Senior Vice President, Chief Financial Officer & Chief Operating Officer(age: 53, pay: $695,820)
- Dr. Jonathan Zalevsky Chief R&D Officer(age: 50, pay: $590,120)
- Ms. Jillian B. Thomsen Senior Vice President of Fin. & Chief Accounting Officer(age: 59, pay: $470,790)
- Mr. John P. Northcott Senior Vice President & Chief Commercial Officer(age: 47, pay: $269,560)
- Mr. Mark A. Wilson Senior Vice President, Gen. Counsel & Sec.
- Dr. Mary Tagliaferri Senior Vice President & Executive Clinical Fellow
- Dr. Brian L. Kotzin Senior Vice President of Clinical Devel. & Head of Immunology Program
- Dr. Kevin Brodbeck Senior Vice President of Manufacturing
- Ms. Jennifer Ruddock Senior Vice President of Strategy & Corporation Affairs
-
How many employees does Nektar Therapeutics have?
As Jul 2024, Nektar Therapeutics employs 137 workers.
-
When Nektar Therapeutics went public?
Nektar Therapeutics is publicly traded company for more then 7 years since IPO on 18 Jul 2018.
-
What is Nektar Therapeutics's official website?
The official website for Nektar Therapeutics is nektar.com.
-
Where are Nektar Therapeutics's headquarters?
Nektar Therapeutics is headquartered at 455 Mission Bay Boulevard South, San Francisco, CA.
-
How can i contact Nektar Therapeutics?
Nektar Therapeutics's mailing address is 455 Mission Bay Boulevard South, San Francisco, CA and company can be reached via phone at +41 54825300.
Nektar Therapeutics company profile:
Nektar Therapeutics
nektar.comLSE
137
Medical - Pharmaceuticals
Healthcare
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
San Francisco, CA 94158
:
ISIN: US6402681083
:
